CELLDEX THERAPEUTICS INC (CLDX) Fundamental Analysis & Valuation

NASDAQ:CLDX • US15117B2025

Current stock price

33.95 USD
-0.43 (-1.25%)
Last:

This CLDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CLDX Profitability Analysis

1.1 Basic Checks

  • CLDX had negative earnings in the past year.
  • In the past year CLDX has reported a negative cash flow from operations.
  • In the past 5 years CLDX always reported negative net income.
  • CLDX had a negative operating cash flow in each of the past 5 years.
CLDX Yearly Net Income VS EBIT VS OCF VS FCFCLDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

  • CLDX has a Return On Assets (-44.38%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -49.08%, CLDX is in the better half of the industry, outperforming 62.40% of the companies in the same industry.
Industry RankSector Rank
ROA -44.38%
ROE -49.08%
ROIC N/A
ROA(3y)-31.56%
ROA(5y)-28.48%
ROE(3y)-34.39%
ROE(5y)-30.88%
ROIC(3y)N/A
ROIC(5y)N/A
CLDX Yearly ROA, ROE, ROICCLDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • CLDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLDX Yearly Profit, Operating, Gross MarginsCLDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CLDX Health Analysis

2.1 Basic Checks

  • CLDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CLDX has more shares outstanding
  • CLDX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for CLDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLDX Yearly Shares OutstandingCLDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CLDX Yearly Total Debt VS Total AssetsCLDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • CLDX has an Altman-Z score of 23.43. This indicates that CLDX is financially healthy and has little risk of bankruptcy at the moment.
  • CLDX has a Altman-Z score of 23.43. This is amongst the best in the industry. CLDX outperforms 88.57% of its industry peers.
  • CLDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.43
ROIC/WACCN/A
WACC9.53%
CLDX Yearly LT Debt VS Equity VS FCFCLDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 10.49 indicates that CLDX has no problem at all paying its short term obligations.
  • CLDX has a Current ratio of 10.49. This is amongst the best in the industry. CLDX outperforms 81.59% of its industry peers.
  • CLDX has a Quick Ratio of 10.49. This indicates that CLDX is financially healthy and has no problem in meeting its short term obligations.
  • CLDX's Quick ratio of 10.49 is amongst the best of the industry. CLDX outperforms 81.59% of its industry peers.
Industry RankSector Rank
Current Ratio 10.49
Quick Ratio 10.49
CLDX Yearly Current Assets VS Current LiabilitesCLDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CLDX Growth Analysis

3.1 Past

  • CLDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.78%.
  • CLDX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -77.98%.
  • Measured over the past years, CLDX shows a very negative growth in Revenue. The Revenue has been decreasing by -26.94% on average per year.
EPS 1Y (TTM)-58.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.83%
Revenue 1Y (TTM)-77.98%
Revenue growth 3Y-13.17%
Revenue growth 5Y-26.94%
Sales Q2Q%-89.7%

3.2 Future

  • Based on estimates for the next years, CLDX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.98% on average per year.
  • Based on estimates for the next years, CLDX will show a very strong growth in Revenue. The Revenue will grow by 223.60% on average per year.
EPS Next Y-26.02%
EPS Next 2Y-12.21%
EPS Next 3Y2.88%
EPS Next 5Y19.98%
Revenue Next Year27.53%
Revenue Next 2Y106.96%
Revenue Next 3Y285.73%
Revenue Next 5Y223.6%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLDX Yearly Revenue VS EstimatesCLDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
CLDX Yearly EPS VS EstimatesCLDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. CLDX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CLDX. In the last year negative earnings were reported.
  • Also next year CLDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLDX Price Earnings VS Forward Price EarningsCLDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLDX Per share dataCLDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.21%
EPS Next 3Y2.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CLDX Dividend Analysis

5.1 Amount

  • No dividends for CLDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLDX Fundamentals: All Metrics, Ratios and Statistics

CELLDEX THERAPEUTICS INC

NASDAQ:CLDX (4/21/2026, 2:28:26 PM)

33.95

-0.43 (-1.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-30
Inst Owners109.92%
Inst Owner Change0%
Ins Owners0.21%
Ins Owner Change2.15%
Market Cap2.61B
Revenue(TTM)1.55M
Net Income(TTM)-258.76M
Analysts82.73
Price Target55.42 (63.24%)
Short Float %11.83%
Short Ratio8.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.26%
Min EPS beat(2)-18.58%
Max EPS beat(2)-9.94%
EPS beat(4)1
Avg EPS beat(4)-7.77%
Min EPS beat(4)-18.58%
Max EPS beat(4)2.62%
EPS beat(8)5
Avg EPS beat(8)1.46%
EPS beat(12)7
Avg EPS beat(12)-0.55%
EPS beat(16)9
Avg EPS beat(16)-0.98%
Revenue beat(2)0
Avg Revenue beat(2)-95.98%
Min Revenue beat(2)-100%
Max Revenue beat(2)-91.97%
Revenue beat(4)0
Avg Revenue beat(4)-63.94%
Min Revenue beat(4)-100%
Max Revenue beat(4)-28.92%
Revenue beat(8)3
Avg Revenue beat(8)17.55%
Revenue beat(12)6
Avg Revenue beat(12)63.38%
Revenue beat(16)8
Avg Revenue beat(16)71.19%
PT rev (1m)8.31%
PT rev (3m)1.83%
EPS NQ rev (1m)-1.23%
EPS NQ rev (3m)-4.6%
EPS NY rev (1m)-3.06%
EPS NY rev (3m)-8.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)36.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1688.5
P/FCF N/A
P/OCF N/A
P/B 4.95
P/tB 5.22
EV/EBITDA N/A
EPS(TTM)-3.89
EYN/A
EPS(NY)-4.9
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.74
OCFYN/A
SpS0.02
BVpS6.86
TBVpS6.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -44.38%
ROE -49.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.56%
ROA(5y)-28.48%
ROE(3y)-34.39%
ROE(5y)-30.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.3%
Cap/Sales 175.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.49
Quick Ratio 10.49
Altman-Z 23.43
F-Score2
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)67.05%
Cap/Depr(5y)60.99%
Cap/Sales(3y)76.47%
Cap/Sales(5y)66.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.83%
EPS Next Y-26.02%
EPS Next 2Y-12.21%
EPS Next 3Y2.88%
EPS Next 5Y19.98%
Revenue 1Y (TTM)-77.98%
Revenue growth 3Y-13.17%
Revenue growth 5Y-26.94%
Sales Q2Q%-89.7%
Revenue Next Year27.53%
Revenue Next 2Y106.96%
Revenue Next 3Y285.73%
Revenue Next 5Y223.6%
EBIT growth 1Y-47.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.96%
EBIT Next 3Y0.04%
EBIT Next 5YN/A
FCF growth 1Y-33.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.7%
OCF growth 3YN/A
OCF growth 5YN/A

CELLDEX THERAPEUTICS INC / CLDX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CELLDEX THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to CLDX.


Can you provide the valuation status for CELLDEX THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CELLDEX THERAPEUTICS INC (CLDX). This can be considered as Overvalued.


How profitable is CELLDEX THERAPEUTICS INC (CLDX) stock?

CELLDEX THERAPEUTICS INC (CLDX) has a profitability rating of 1 / 10.


What is the financial health of CELLDEX THERAPEUTICS INC (CLDX) stock?

The financial health rating of CELLDEX THERAPEUTICS INC (CLDX) is 8 / 10.


What is the expected EPS growth for CELLDEX THERAPEUTICS INC (CLDX) stock?

The Earnings per Share (EPS) of CELLDEX THERAPEUTICS INC (CLDX) is expected to decline by -26.02% in the next year.